September 17, 2018, 4:00 - 6:30 PM
Lower Auditorium
Medical Education and Telemedicine Building (MET)
Auditoria & Courtyard Osler Lane
San Diego, CA 92161
On September 5, 2018 the University of California San Diego (UC San Diego) and Deerfield Management announced the creation of Poseidon Innovation, LLC to advance disease-curing therapeutics. Through Deerfield’s $65-million commitment in Poseidon, UC San Diego investigators will have the funding and support to weather risky early-stage processes and expedite the drug-development cycle, allowing patients to receive treatment faster.
Poseidon leverages UC San Diego’s courage to dissect convention, and together with Deerfield, creates cross-disciplinary, flexible approaches to advance research and break down silos that often cause roadblocks to advancement.
Projects that enter Poseidon will be directed by a joint steering committee and have access to sufficient funding for a full drug development program. Investigational New Drug (IND) application-enabling work will be done in labs on campus and externally.
Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy. For more information, please visit www.deerfield.com.
As one of the top 15 research universities in the world, UC San Diego is driving innovation and change to advance society, propel economic growth and make our world a better place. Learn more at www.ucsd.edu.
Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy. For more information, please visit www.deerfield.com.
As one of the top 15 research universities in the world, UC San Diego is driving innovation and change to advance society, propel economic growth and make our world a better place. Learn more at www.ucsd.edu.
